IMAX CORP (IMAX)

CA45245E1097 - Common Stock

15.3  +0.02 (+0.13%)

Buy % Consensus

80

ChartMill assigns a Buy % Consensus number of 80% to IMAX. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 23.05. This target is 50.67% above the current price.
IMAX was analyzed by 16 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about IMAX.
In the previous month the buy percentage consensus was at a similar level.
IMAX was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 15.3013.1323.4623.0531.50 - -14.18% 53.33% 50.67% 105.88%
Up and Down Grades
Date Firm Action Rating
2024-02-13 Rosenblatt Maintains Buy -> Buy
2024-02-06 JP Morgan Maintains Neutral -> Neutral
2024-01-18 Benchmark Maintains Buy -> Buy
2024-01-11 Goldman Sachs Maintains Sell -> Sell
2024-01-02 B. Riley Securities Maintains Buy -> Buy
2023-12-05 Rosenblatt Reiterate Buy -> Buy
2023-10-10 Rosenblatt Reiterate Buy -> Buy
2023-10-09 Benchmark Maintains Buy -> Buy
2023-08-25 Rosenblatt Maintains Buy -> Buy
2023-08-18 Rosenblatt Maintains Buy -> Buy
2023-07-28 Barrington Research Reiterate Outperform -> Outperform
2023-07-27 Rosenblatt Maintains Buy -> Buy
2023-07-27 Wedbush Reiterate Outperform -> Outperform
2023-07-20 Wedbush Reiterate Outperform -> Outperform
2023-07-13 Benchmark Reiterate Buy -> Buy
2023-07-13 Rosenblatt Reiterate Buy -> Buy
2023-07-13 Wedbush Reiterate Outperform -> Outperform
2023-07-12 Roth MKM Reiterate Buy -> Buy
2023-05-02 Barrington Research Reiterate Outperform
2023-05-02 Benchmark Maintains Buy
2023-04-28 Roth MKM Maintains Buy
2023-04-28 Rosenblatt Maintains Buy
2023-04-28 B. Riley Securities Maintains Buy
2023-04-28 Wells Fargo Maintains Overweight
2023-04-25 Wedbush Maintains Outperform
2023-04-10 B. Riley Securities Maintains Buy
2023-04-05 Rosenblatt Reiterate Buy
2023-02-28 Goldman Sachs Maintains Sell
2023-02-23 Barrington Research Reiterate Outperform
2023-02-23 Rosenblatt Maintains Buy